The Global Market for DNA Probes-based Diagnostics is Projected to Reach US$20.2 Billion by 2022
Rising Demand for Infectious
Disease Testing Drives the DNA Probes-Based Diagnostics Market, According to a New
Report by Global
Industry Analysts, Inc.
GIA launches comprehensive analysis of industry
segments, trends, growth drivers, market share, size and demand forecasts on
the global DNA Probes-based Diagnostics market. The global market for DNA
Probes-based Diagnostics is projected to reach US$20.2 billion by 2022, driven by the growing use
of DNA Probes in infectious disease testing, development of new methods for
high-volume testing, launch of new equipment facilitating execution of tests in
a rapid and simple manner, newer technologies and innovation that enhances test
accuracy, speed, and reliability.
The global market for DNA probes-based diagnostics
is expected to witness stable growth in the coming years, driven by factors
such as rising awareness among consumers, aging population, rise in genetic
disorders, technological developments as well as higher investments in
pharmaceutical research. In addition to medical diagnostics, the DNA
Probes-based technology is expected to grow considerably in other application
areas, including surface chemistry, instrumentation development, data handling,
molecular biology, biological sample preparation, microfabrication and
molecular detection. In the [medical diagnostics] sector, DNA Probes-based
diagnostics are used in identifying genetic predispositions, infectious
diseases, molecular HLA typing, forensics, and cancer testing, among others.
Infectious
disease testing is witnessing a growth spurt supported by the emergence of new infectious
threats, such as new strains of HIV, H1N1, and multidrug-resistant tuberculosis
etc. HPV diagnostic testing offers enormous growth opportunities as only a small
share of women (aged over 30 years) are screened for HPV under the current
standard of care involving pap smear and other DNA-based tests. However, as the
technology climbs up the knowledge curve, falling costs are expected to make
DNA based diagnostics affordable, more common and easy-to-use. Moreover, with
newer MDx being developed along with rapid adoption of molecular
biomarker
assays, the market will continue to witness steady gains. Despite the
opportunities for growth, the market is currently limited by high prices,
technology loopholes/bottlenecks, and lack of standardization across test
platforms.
Prenatal DNA testing is used to detect fetal
chromosomal abnormalities, with same efficacy as invasive techniques such as
CVS and amniocentesis, but without the risk of miscarriage. Therefore, it is
being increasingly preferred to serve women with a high risk of carrying babies
with chromosomal aneuploidies that may result in Down syndrome, among others.
The tests are also covered by most U.S. health insurers. Nevertheless,
DNA-based tests are still considered as screening tools. Positive test cases
are recommended to be confirmed with conventional amniocentesis. However,
invasive confirmatory tests can now only be restricted to only high-risk
population.
As
stated by the new market research report on DNA Probes-based Diagnostics, the U.S. and Europe constitute key markets worldwide
with 80%-90% of tests being conducted in these regions. Emerging markets of
Asia-Pacific and Latin America are forecast to spur future growth supported by
government funding in medical research, introduction of advanced technologies,
robust network of pharmaceutical and biotechnology industries. Asia-Pacific ranks
as the fastest growing market, with a CAGR of 14.8% over the analysis period. Emerging Asian economies offer high potential given
its large population base, rising healthcare burden, improving awareness, and access
to medical products and services.
Major players in the market
include Abbott Molecular, Beckman
Coulter Inc., Becton, Dickinson and Company, bioMérieux, F. Hoffmann-La Roche
Ltd., GE Healthcare Life Sciences, Luminex Corporation, QIAGEN N.V., Siemens
Healthineers and Thermo Fisher Scientific Inc. among others.
The research report titled
"DNA Probes-based Diagnostics:
A Global Strategic Business Report" announced by Global Industry Analysts Inc.,
provides a comprehensive review of market trends, growth drivers, mergers and
acquisitions, and other strategic industry activities of major companies
worldwide. The report provides market estimates and projections for geographic
markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain,
Russia, and Rest of Europe), Asia-Pacific, and Rest of World.
For
enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.
To
connect with us, visit our LinkedIn page.
Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA,
All Rights Reserved.
Comments
Post a Comment